REFERENCES
- Nelson LS, Perrone J. Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS). JAMA. 2012;308:457–458.
- Substance Abuse and Mental Health Services Administration. Results From the 2010 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2011. NSDUH Series H–41, HHS Publication No. (SMA) 11–4658.
- Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR Morb Mort Wkly Rep. 2011;60:1487–1492.
- Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31:207–225.
- Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction. 2001:96:683–690.
- Castells X, Kosten T, Capella D, et al. Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with co-morbid cocaine use disorders: a systematic review and meta-analysis of controlled clinical trials. The American Journal of Drug and Alcohol Abuse. 2009;35:339–349.
- Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11:1–171.
- Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance verse placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;(2):CD002207.
- Curcio F, Franco T, Topa M, et al. Buprenorphine/naloxone verse methadone in opioid dependence: a longitudinal survey. Eur Rev Pharmacol Sci. 2011;15:871–874.
- Marsch LA, Stephens MAC, Mudric T, Strain EC, Bigelow GE, Johnson RE. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. Experimental and Clinical Psychopharmacology. 2005;13:293–302.
- Doran C, Shanahan M, Mattick RP, Ali R, White J, Bell J. Buprenorphine verse methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend. 2003;71:295–302.
- Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Int Med. 2011;27:669–676.
- Tetrault JM, Moore BA, Barry DT, et al. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients. J Subst Abuse Treat. 2012;43:433–439.
- Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychol. 2011;68:1238–1246.